Emergent BioSolutions Inc. provided earnings guidance for the full year 2022. For the year, the company expects total revenues of $1,400 million to $1,500 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.82 USD | -2.29% |
|
+4.60% | +184.17% |
20/06 | Benchmark Adjusts Emergent Biosolutions Price Target to $8 From $5, Maintains Buy Rating | MT |
02/05 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+184.17% | 357M | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- EBS Stock
- News Emergent BioSolutions Inc.
- Emergent BioSolutions Inc. Provides Earnings Guidance for the Full Year 2022